Comparative Pharmacology
Head-to-head clinical analysis: FIORICET W CODEINE versus QDOLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FIORICET W CODEINE versus QDOLO.
FIORICET W/ CODEINE vs QDOLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FIORICET W/ CODEINE combines butalbital (barbiturate) that enhances GABA-A receptor activity, acetaminophen (analgesic/antipyretic) that inhibits cyclooxygenase and modulates cannabinoid receptors, and codeine (opioid mu-receptor agonist) that activates mu-opioid receptors to produce analgesia and antitussive effects.
Tramadol is a centrally acting synthetic opioid analgesic. It binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
1-2 capsules orally every 4 hours as needed, maximum 6 capsules per day.
Oral: 50-100 mg every 4-6 hours as needed for pain; maximum 400 mg per day. Immediate-release tablets only. Extended-release formulations require different dosing and are not interchangeable.
None Documented
None Documented
Codeine: 2.5-3.5 hours (converted to morphine; clinical effect wanes accordingly). Acetaminophen: 1.5-2.5 hours. Butalbital: 35-40 hours (prolonged in hepatic impairment; contributes to sedation). Caffeine: 3-5 hours.
Terminal elimination half-life approximately 2-4 hours in adults; prolonged to 4-6 hours in elderly and up to 12-16 hours in severe renal impairment (CrCl <30 mL/min)
Codeine and its metabolites are primarily excreted renally (about 90% as conjugates and free drug). Acetaminophen is excreted renally as conjugates (85-90%) and as unchanged drug (<5%). Butalbital is excreted renally (about 90% as metabolites and unchanged). Caffeine metabolites are excreted renally. Fecal excretion is minimal.
Renal 90% (60% unchanged, 30% as glucuronide conjugate), fecal 10%
Category D/X
Category C
Opioid Agonist
Opioid Agonist